Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Turnstone Biologics raises $41.4mm through Series B round

Executive Summary

Turnstone Biologics Inc. (cancer therapies) raised $41.4mm through its Series B round from new investors OrbiMed and F-Prime (which both take board seats), along with returning backers FACIT and Versant Ventures. Funds will support completion (in 2017) of an ongoing Phase I/II trial with Turnstone's lead oncolytic Maraba virus candidate for melanoma. The company plans to expand indications for that therapy (in combination with a checkpoint inhibitor) to include non-small cell lung cancer later this year, and will also continue work on two additional preclinical Maraba virus-based therapies for other cancers.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register